Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | DYRK1A | Q13627 | 3/20 | 0.46 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.46 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.46 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.46 |
| ▸ | PTPRC | P08575 | 1/20 | 0.44 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.44 |
| ▸ | PTPN11 | Q06124 | 1/20 | 0.44 |
| ▸ | PTPN22 | Q9Y2R2 | 1/20 | 0.44 |
| ▸ | CTNNB1 | P35222 | 1/20 | 0.43 |
| ▸ | WNT3A | P56704 | 1/20 | 0.43 |
| ▸ | CLK1 | P49759 | 2/20 | 0.41 |
| ▸ | DYRK1B | Q9Y463 | 2/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CA2 | P00918 | 3/20 | 0.40 |
| ▸ | ESR1 | P03372 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.39 |
| ▸ | CA12 | O43570 | 2/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30656341 | 1.00 | CYP2A6 (0.50) | CYP2A6DYRK1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL15537714 | 0.83 | DYRK1A (0.58) | CYP2A6DYRK1ACA2ESR1ESR2 | |
| SCHEMBL29766115 | 0.81 | ESR1 (0.44) | CYP2A6SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL911044 | 0.81 | ESR1 (0.44) | CYP2A6SLC6A2SLC6A4SLC6A3CYP1A2 | |
| SCHEMBL164774 | 0.73 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL3480312 | 0.73 | CYP2A6 (0.42) | CYP2A6DYRK1ASLC6A2SLC6A4SLC6A3 | |
| SCHEMBL17010916 | 0.73 | CYP2A6 (0.52) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL18725846 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL2011544 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1APTPRCPTPN6PTPN11 | |
| SCHEMBL155613 | 0.71 | CYP2A6 (0.50) | CYP2A6DYRK1ASLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 295 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1528060-A1 | Process for preparing 5-hydroxy[b]thiophene-3-carboxylic acid derivatives | SHIONOGI & CO., LTD. (JP) | 2005-05-04 | — | — | EP | claimed |
| EP-0975740-B1 | METHOD FOR ENHANCING THE ACTIVITY OF AN ENZYME, BLEACH COMPOSITION, DETERGENT COMPOSITION AND PROCESS FOR INHIBITING DYE TRANSFER | UNILEVER NV (NL) | 2004-09-08 | — | — | EP | claimed |
| US-6495702-B2 | SPECIFIC PGD2 ANTAGONISTS; STARTING MATERIALS FOR PRODUCING DRUGS | SHIONOGI & CO., LTD. (JP) | 2002-12-17 | — | — | US | claimed |
| US-20020026061-A1 | Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives | HONMA TSUNETOSHI (JP) | 2002-02-28 | — | — | US | claimed |
| US-6346628-B1 | REACTING 4-MERCAPTOPHENOL WITH A PROPARYGL GOUP AND PROTECTION OF HYDROXYL GROUP, OXIDIZING THE PRODUCT, AND THERMAL REARRANGEMENT TO CYCLIZE, FOLLOWED BY FURTHER OXIDATION | SHIONOGI & CO., LTD. (JP) | 2002-02-12 | — | — | US | claimed |
| US-20020016476-A1 | PROCESS FOR PREPARING 5-HYDROXYBENZO [B] THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | HONMA TSUNETOSHI (JP) | 2002-02-07 | — | — | US | claimed |
| US-6225275-B1 | ACTIVATION OF OXIDOREDUCTASES FOR BLEACHING FABRICS DURING WASHING | LEVER BROTHERS COMPANY, DIVISION OF CONOPCO, INC. | 2001-05-01 | — | — | US | claimed |
| EP-1069122-A1 | PROCESS FOR PRODUCING 5-HYDROXYBENZO b]THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | SHIONOGI & CO., LTD. (JP) | 2001-01-17 | — | — | EP | claimed |
| EP-0975740-A1 | METHOD FOR ENHANCING THE ACTIVITY OF AN ENZYME, BLEACH COMPOSITION, DETERGENT COMPOSITION AND PROCESS FOR INHIBITING DYE TRANSFER | UNILEVER N.V. (NL) | 2000-02-02 | — | — | EP | claimed |
| WO-1998056899-A1 | METHOD FOR ENHANCING THE ACTIVITY OF AN ENZYME, BLEACH COMPOSITION, DETERGENT COMPOSITION AND PROCESS FOR INHIBITING DYE TRANSFER | UNILEVER N.V. (NL) | 1998-12-17 | — | — | WO | claimed |
| WO-2026100621-A1 | ELECTROLESS NICKEL PLATING SOLUTION, ELECTROLESS NICKEL PLATING METHOD, NICKEL PLATING FILM, AND PRODUCT | 奥野製薬工業株式会社 | 2026-05-15 | — | — | WO | disclosed |
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | UNIV LEUVEN KATH (BE) | 2025-11-13 | — | — | US | disclosed |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | HERCULES CAPITAL, INC., AS AGENT | 2025-09-11 | — | — | US | disclosed |
| US-12344610-B2 | APOL1 inhibitors and methods of use | MAZE THERAPEUTICS, INC. (US) | 2025-07-01 | — | — | US | disclosed |
| WO-2025046419-A1 | NOVEL COMPOUND AS NLRP3 INHIBITOR AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 제일약품주식회사 | 2025-03-06 | — | — | WO | disclosed |
| WO-1994007875-A1 | HETEROCYCLIC AMINES HAVING COLMODULIN ANTAGONIST PROPERTIES | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1994-04-14 | — | — | WO | disclosed |
| US-5254595-A | Aryloxypropanolaminotetralins, a process for their preparation and pharmaceutical compositions containing them | ELF SANOFI (FR) | 1993-10-19 | — | — | US | disclosed |
| EP-0375560-B1 | ARYLOXYPROPANOLAMINOTETRALINES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING SAME | ELF SANOFI (FR) | 1993-05-12 | — | — | EP | disclosed |
| US-4963580-A | ANTIINFLAMMATORY AGENTS | MERCK & CO., INC. (US) | 1990-10-16 | — | — | US | disclosed |
| EP-0375560-A1 | Aryloxypropanolaminotetralines, process for their preparation and pharmaceutical compositions containing same | ELF SANOFI (FR) | 1990-06-27 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020016476-A1 | PROCESS FOR PREPARING 5-HYDROXYBENZO [B] THIOPHENE-3-CARBOXYLIC ACID DERIVATIVES | HPD, PTGDR2, PTGS2 | CYP2A6 53/4885DYRK1A 4357/4885SLC6A2 1370/4885 |
| US-12344610-B2 | APOL1 inhibitors and methods of use | APOL1, APOB, PON1 | CYP2A6 2441/4885DYRK1A 3836/4885SLC6A2 1119/4885 |
| US-20250346569-A1 | NEW DERIVATIVES FOR TREATING TRPM3 MEDIATED DISORDERS | TRPM4, TRPM2, TRPM6 | CYP2A6 1825/4885DYRK1A 3747/4885SLC6A2 1020/4885 |
| US-20020026061-A1 | Process for preparing 5-hydroxybenzo [b] thiophene-3-carboxylic acid derivatives | HPD, PTGDR2, PTGS2 | CYP2A6 53/4885DYRK1A 4357/4885SLC6A2 1370/4885 |
| US-20250282781-A1 | APOL1 INHIBITORS AND METHODS OF USE | APOL1, APOB, PON1 | CYP2A6 2441/4885DYRK1A 3836/4885SLC6A2 1119/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.